Quick answer: Tesamorelin is a synthetic GHRH analog that is FDA-approved under the brand name Egrifta for HIV-associated lipodystrophy, but it is not licensed in the UK. Research-grade tesamorelin sold for laboratory use is a different product category from the prescription biologic. The clinical evidence base for the compound is substantial, with a Phase 3 trial programme supporting the FDA approval. Alta Peptides publishes lot-specific certificates of analysis for its research-grade tesamorelin, which is the baseline standard any researcher should expect before ordering.
Search for “tesamorelin UK” and you will find a market that reflects the compound’s unusual position: it is an FDA-approved drug, but it is not licensed in the UK, and the research peptide sold online is a separate category from the prescription biologic. Understanding the differences between these categories is essential for anyone considering tesamorelin in a research context.
This guide explains what tesamorelin is, what the published clinical data shows, how the FDA-approved version differs from research-grade material, and what documentation to verify before sourcing.
What tesamorelin is
Tesamorelin is a synthetic analog of human growth hormone-releasing factor (GRF), also known as growth hormone-releasing hormone (GHRH). It is composed of the 44-amino-acid sequence of human GRF with a trans-3-hexenoyl group attached to the N-terminus, a modification designed to increase its half-life over that of native GHRH(1-44). The compound binds to and stimulates GHRH receptors in the pituitary, promoting the pulsatile release of endogenous growth hormone and subsequently increasing IGF-1 and IGFBP-3 levels.
The compound was approved by the FDA in 2010 under the brand name Egrifta for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It is manufactured by Theratechnologies Inc. under a Biologics License Application. It has not received a marketing authorisation from the MHRA in the UK.
What the clinical data shows
The clinical evidence base for tesamorelin is substantial. A study published in the New England Journal of Medicine in 2007 evaluated the effects of tesamorelin on visceral adipose tissue in patients with HIV and abdominal fat accumulation. The study was a randomised, double-blind, placebo-controlled trial involving 412 patients.
Participants received daily subcutaneous injections of either 2mg of tesamorelin or placebo for 26 weeks. The primary endpoint was the change in visceral adipose tissue, measured by CT scan. The results showed a 15.2 percent decrease in visceral adipose tissue in the tesamorelin group and a 5.0 percent increase in the placebo group. Triglyceride levels decreased by 50mg/dL in the tesamorelin group compared to an increase of 9mg/dL in the placebo group. IGF-1 levels increased by 81.0 percent in the tesamorelin group and decreased by 5.0 percent in the placebo group.
A pooled analysis published in the Journal of Clinical Endocrinology and Metabolism in 2010 examined the effects of tesamorelin across two multicentre, double-blind, placebo-controlled Phase 3 trials. The authors concluded that tesamorelin reduced visceral adiposity and improved plasma lipids while preserving subcutaneous tissue with up to 52 weeks of treatment.
The NIH LiverTox monograph on tesamorelin summarises the drug’s clinical use and notes that tesamorelin has not been linked to serum aminotransferase elevations or to clinically apparent acute liver injury.
What the research does not establish is a safe and effective dose for any human use outside of the approved indication. The clinical literature describes tesamorelin in a specific patient population, with specific monitoring protocols. Those conditions cannot be replicated by purchasing a research vial online.
The difference between Egrifta and research-grade tesamorelin
Researchers need to understand a distinction that is often blurred in online listings. Egrifta is an FDA-approved prescription biologic manufactured under a Biologics License Application. The tesamorelin sold by research peptide suppliers is a lyophilised powder labelled for laboratory research use only, not for diagnostic, therapeutic, or human use.
The Alta Peptides tesamorelin product page lists the research-grade product alongside the current lot documentation and price. The company maintains a research-use-only boundary throughout its product descriptions and does not publish dosing or administration guidance.
The distinction matters because the regulatory framework around a prescription biologic is entirely different from the framework around a research chemical. A supplier that sells research-grade tesamorelin and markets it as equivalent to Egrifta is misrepresenting the product. A supplier that maintains the research-use boundary and provides analytical documentation is operating within a recognised research supply channel.
Sourcing considerations in the UK
Tesamorelin is not licensed in the UK, so there is no prescription route to access the compound. Research-grade tesamorelin sold for laboratory use occupies a different regulatory space from licensed medicines. The research-use-only designation is a legal boundary that restricts the product to laboratory use.
For researchers, the documentation is the starting point. A supplier that publishes lot-specific certificates of analysis from a named independent laboratory, with identity, purity, and measured content reported as separate measurements, is operating at a different standard than one that publishes only a purity percentage.
Why mitochondrial and metabolic peptides are studied together
Tesamorelin is sometimes discussed alongside other peptides studied for metabolic effects, including mitochondrial-derived peptides such as MOTS-c. The two compounds operate through different mechanisms: tesamorelin stimulates growth hormone release through the GHRH receptor, while MOTS-c regulates metabolic homeostasis through AMPK activation. The Alta Peptides overview of MOTS-c and epitalon explains the research context for these compounds.
Video: Tesamorelin explained
This third-party video provides general context on tesamorelin research. It is not affiliated with Alta Peptides and is not a substitute for laboratory documentation or the published literature.
How Alta Peptides approaches tesamorelin documentation
Alta Peptides is a UK-based research peptide supplier that publishes lot-specific documentation for each product configuration. The company’s journal publishes educational content on peptide handling, storage, and certificate interpretation.
The tesamorelin product page shows the current lot report alongside the price, with the testing laboratory and report ID visible for cross-referencing. The company maintains a research-use-only boundary throughout its product descriptions.
Comparing tesamorelin categories
| Feature | Egrifta (FDA-approved) | Research-grade tesamorelin |
|---|---|---|
| Regulatory status | Approved by FDA, not licensed in UK | Research-use-only |
| Format | Prescription biologic | Lyophilised powder |
| Intended use | HIV-associated lipodystrophy | Laboratory research |
| Documentation | Prescribing information | Lot-specific COA |
Common questions about tesamorelin
Is tesamorelin licensed in the UK?
No. Tesamorelin has not received a marketing authorisation from the MHRA. It is FDA-approved in the United States under the brand name Egrifta for a specific indication, but it is not available by prescription in the UK. Research-grade tesamorelin sold for laboratory use occupies a different regulatory space.
What does the clinical data show?
The Phase 3 trial published in the New England Journal of Medicine showed a 15.2 percent decrease in visceral adipose tissue in the tesamorelin group compared with a 5.0 percent increase in the placebo group. A pooled analysis published in 2010 confirmed these findings across two Phase 3 trials.
What should a tesamorelin COA show?
A complete COA should report identity by mass spectrometry, purity by HPLC with the method stated, measured content or assay value, endotoxin testing, and sterility testing. It should also include the lot number, the testing laboratory’s name, the report ID, and the dates of sample receipt and result reporting.
How do I verify that a COA is real?
Check that the testing laboratory is named and that the report ID can be cross-referenced. Some laboratories publish verification portals where a report ID can be entered to confirm the document’s authenticity. If the supplier cannot identify which laboratory performed the test, the certificate cannot be independently verified.
What is the difference between tesamorelin and TH9507?
TH9507 is a designation used for tesamorelin in the research literature. The compound is the same. Researchers should confirm the identity of any product by its COA, not by the brand name or research designation on the vial.
What should I do if a supplier’s listing makes health claims?
Treat it as a disqualifying signal. Health claims on a research peptide listing are the exact pattern that regulators have cited in enforcement actions. A supplier that describes what the peptide “does” for the body is marketing an unapproved drug, regardless of the research-use label elsewhere on the page.
Disclaimer: This article is for informational purposes only and does not constitute legal, medical, or regulatory advice. Tesamorelin is an FDA-approved prescription drug in the United States under the brand name Egrifta, but it is not licensed in the UK. Research peptides are sold for laboratory research purposes only. Nothing in this article should be interpreted as guidance for human use, dosing, or administration. Researchers are responsible for complying with all applicable laws and regulations in their jurisdiction. Consult a qualified professional before making decisions about any substance. Alta Peptides is a supplier of research peptides; this article is editorial content and is not a product endorsement.